Sign Out
Pregnancy: There are limited post‑marketing data on the use of domperidone in pregnant women. A study in rats has shown reproductive toxicity at a high, maternally toxic dose. The potential risk for humans is unknown. Therefore, domperidone (Motilium) should only be used during pregnancy when justified by the anticipated therapeutic benefit.
Breast-feeding: The amount of domperidone that could be ingested by an infant through breast milk is low. The maximal relative infant dose (%) is estimated to be about 0.1% of the maternal weight‑adjusted dosage. It is not known whether this is harmful to the newborn. Therefore, breastfeeding is not recommended for women who are taking domperidone (Motilium).
Continue with Google